Am J Epidemiol 2004; 159:623-633.
Copyright © 2004 by the Johns
Hopkins Bloomberg School of Public Health
SPECIAL ARTICLE |
Containing Pandemic Influenza with Antiviral Agents
From the Department of Biostatistics, The Rollins School of Public Health, Emory University, Atlanta, GA.
For the first wave of pandemic influenza or a bioterrorist influenza attack, antiviral agents would be one of the few options to contain the epidemic in the United States until adequate supplies of vaccine were available. The authors use stochastic epidemic simulations to investigate the effectiveness of targeted antiviral prophylaxis to contain influenza. In this strategy, close contacts of suspected index influenza cases take antiviral agents prophylactically. The authors compare targeted antiviral prophylaxis with vaccination strategies. They model an influenza pandemic or bioterrorist attack for an agent similar to influenza A virus (H2N2) that caused the Asian influenza pandemic of 1957–1958. In the absence of intervention, the model predicts an influenza illness attack rate of 33% of the population (95% confidence interval (CI): 30, 37) and an influenza death rate of 0.58 deaths/1,000 persons (95% Cl: 0.4, 0.8). With the use of targeted antiviral prophylaxis, if 80% of the exposed persons maintained prophylaxis for up to 8 weeks, the epidemic would be contained, and the model predicts a reduction to an illness attack rate of 2% (95% Cl: 0.2, 16) and a death rate of 0.04 deaths/1,000 persons (95% CI: 0.0003, 0.25). Such antiviral prophylaxis is nearly as effective as vaccinating 80% of the population. Vaccinating 80% of the children aged less than 19 years is almost as effective as vaccinating 80% of the population. Targeted antiviral prophylaxis has potential as an effective measure for containing influenza until adequate quantities of vaccine are available.
antiviral agents; bioterrorism; computer simulation; disease outbreaks; influenza; influenza A virus; influenza vaccine; Monte Carlo method
Abbreviations: Abbreviations: AVE, antiviral efficacy; AVED, antiviral efficacy for symptomatic disease given infection; AVEI, antiviral efficacy for infectiousness; AVES, antiviral efficacy for susceptibility to infection; AVESD, antiviral efficacy for symptomatic disease; CI, confidence interval; R, reproductive number; R0, basic reproductive number; VEI, vaccine efficacy for infectiousness; VES, vaccine efficacy for susceptibility; VEIII, overall effectiveness.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Nuno, T. A. Reichert, G. Chowell, and A. B. Gumel Protecting residential care facilities from pandemic influenza PNAS, July 29, 2008; 105(30): 10625 - 10630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Carrat, E. Vergu, N. M. Ferguson, M. Lemaitre, S. Cauchemez, S. Leach, and A.-J. Valleron Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies Am. J. Epidemiol., April 1, 2008; 167(7): 775 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Halloran, N. M. Ferguson, S. Eubank, I. M. Longini Jr., D. A. T. Cummings, B. Lewis, S. Xu, C. Fraser, A. Vullikanti, T. C. Germann, et al. Modeling targeted layered containment of an influenza pandemic in the United States PNAS, March 25, 2008; 105(12): 4639 - 4644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lofgren, N. H. Fefferman, Y. N. Naumov, J. Gorski, and E. N. Naumova Influenza Seasonality: Underlying Causes and Modeling Theories J. Virol., June 1, 2007; 81(11): 5429 - 5436. [Full Text] [PDF]
|
|
|
|
|
|
A. P. Galvani, T. C. Reluga, and G. B. Chapman Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum PNAS, March 27, 2007; 104(13): 5692 - 5697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Halloran, F. G. Hayden, Y. Yang, I. M. Longini Jr, and A. S. Monto Antiviral Effects on Influenza Viral Transmission and Pathogenicity: Observations from Household-based Trials Am. J. Epidemiol., January 15, 2007; 165(2): 212 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Halloran Invited Commentary: Challenges of using Contact Data to Understand Acute Respiratory Disease Transmission Am. J. Epidemiol., November 15, 2006; 164(10): 945 - 946. [Full Text] [PDF]
|
|
|
|
|
|
J. Wallinga, P. Teunis, and M. Kretzschmar Using Data on Social Contacts to Estimate Age-specific Transmission Parameters for Respiratory-spread Infectious Agents Am. J. Epidemiol., November 15, 2006; 164(10): 936 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Ball and O. Lyne Optimal vaccination schemes for epidemics among a population of households, with application to variola minor in Brazil Statistical Methods in Medical Research, October 1, 2006; 15(5): 481 - 497. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Doyle, I. Bonmarin, D. Levy-Bruhl, Y. L. Strat, and J.-C. Desenclos Influenza pandemic preparedness in France: modelling the impact of interventions J. Epidemiol. Community Health, May 1, 2006; 60(5): 399 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Germann, K. Kadau, I. M. Longini Jr., and C. A. Macken From the Cover: Mitigation strategies for pandemic influenza in the United States PNAS, April 11, 2006; 103(15): 5935 - 5940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Plemper, J. Doyle, A. Sun, A. Prussia, L.-T. Cheng, P. A. Rota, D. C. Liotta, J. P. Snyder, and R. W. Compans Design of a Small-Molecule Entry Inhibitor with Activity against Primary Measles Virus Strains Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3755 - 3761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Longini Jr., A. Nizam, S. Xu, K. Ungchusak, W. Hanshaoworakul, D. A. T. Cummings, and M. E. Halloran Containing Pandemic Influenza at the Source Science, August 12, 2005; 309(5737): 1083 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Longini Jr. and M. E. Halloran Strategy for Distribution of Influenza Vaccine to High-Risk Groups and Children Am. J. Epidemiol., February 15, 2005; 161(4): 303 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rezza Avian influenza: a human pandemic threat? J. Epidemiol. Community Health, October 1, 2004; 58(10): 807 - 808. [Full Text] [PDF]
|
|